App-Quantinova.ai

Prognostic value of a BCSC-associated microRNA signature in hormone receptor-positive HER2-negative breast cancer.

Chang Gong - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Goserelin plus tamoxifen versus tamoxifen alone in pre-or peri-menopausal patients with hormone receptor-positive early-stage breast cancer: A randomized, controlled clinical trial in China.

Hongjian Yang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Tamoxifen

Treatment outcome and prognostic factors in male patients with stage IV breast cancer: A population-based study.

Ying Huang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

A Double-Blind Randomized Phase II/III Trial of Active Immunotherapy with Globo H-KLH (OPT-822) in Subjects with Metastatic Breast Cancer

Chiun-Sheng Huang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Cyclophosphamide

Utidelone Plus Capecitabine vs Capecitabine for Anthracycline- and Taxane-Refractory MBC: A Multicenter, Randomized Phase III Trial (BG01-1312L)

Binghe Xu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Capecitabine

Cbcsg-10: Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer.

Shao Zhimin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

Cyclophosphamide

Effect of miRNA-205 on VEGFA and FGF2 and on resistance to chemotherapeutics in breast cancer.

Yunhui Hu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Doxorubicin

The impact of tumor-to-nipple distance and multicentricity on occult nipple-areola complex involvement and local recurrence in the setting of nipple-sparing mastectomy: A meta-analysis and systematic review.

Hai-Tong Lyu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Comparison of four cycles epirubicin and cyclophosphamide (EC) followed by four cycles docetaxel (T) versus six cycles docetaxel and carboplatin (TP) as adjuvant chemotherapy for women with operable triple negative breast cancer.

Peng Yuan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

Cyclophosphamide

A measure of intratumor heterogeneity to predict metastasis and metastasis-free survival in patients with triple-negative breast cancer.

Yucai Wang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

N/A

Whole genome sequencing (WGS) to reveal the distinct genomic landscape of pulmonary lymphoepithelioma-like carcinoma (LELC).

Shaodong Hong - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pulmonary lymphoepithelioma-like carcinoma

N/A

Circulating tumor DNA mutational profiling by targeted next generation sequencing guides personalized treatments in multiple cancer types.

Yang Shao - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Nomograms to predict the presence of EGFR mutations and ALK rearrangements in non-small-cell lung carcinoma.

Wenfeng Fang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

LAG 3/MHC 2 and PD 1/PD L1 expression in non-small cell lung cancer patients.

Yayi He - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors.

Jayesh Desai - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Tislelizumab

Efficacy of panitumumab vs cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer treated with prior bevacizumab: Results from ASPECCT.

Marc Peeters - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Bevacizumab

Primary tumor location and bevacizumab effectiveness in metastatic colorectal cancer patients.

Wen-zhuo He - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Bevacizumab

Genotype-driven study of weekly irinotecan and capecitabine in combination with neoadjuvant radiotherapy of locally advanced rectal cancer.

Zhen Zhang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Capecitabine

Phase I/II safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of the CheckMate-040 dose escalation study.

Anthony B. El-Khoueiry - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Nivolumab

Phase III Randomized Study of Second Line ADI-Peg 20 (A) Plus Best Supportive Care Versus Placebo (P) Plus Best Supportive Care in Patients with Advanced Hepatocellular Carcinoma

Ghassan K. Abou-Alfa - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Pegargiminase

Filters

24782 Abstracts